权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular Pathology and Genomics Core

分子病理学和基因组学核心

基本信息

批准号：
10005248
负责人：
JON C. ASTER
金额：
$ 25.18万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10005248
关键词：
Academic Medical Centers Address BCL1 Oncogene BCL2 gene Biological Markers Boston CLIA certified Cancer Center Cells Cities Classification Collection Color Complement Consensus DNA Dana-Farber Cancer Institute Data Data Analyses Development Diagnosis Diagnostic Equipment Evaluation Formalin Functional disorder Genes Genomics Genotype Hematologic Neoplasms Hematopathology Histology Histopathology Hospitals Human IL2RA gene Immune Immune response Immunofluorescence Immunologic In Situ Institution International Knowledge Link Lymphoma MCL1 gene MDM2 gene Medical Genetics Memorial Sloan-Kettering Cancer Center Modeling Mus Mutate Normal tissue morphology North Carolina Paraffin Embedding Pathologic Pathologist Pathology Periodicity Peripheral Primary Neoplasm Protocols documentation Research Research Personnel Resistance Resource Sharing Resources STAT5B gene Sampling Services Site Slide Stains System Systems Analysis T-Cell Lymphoma TP53 gene Testing Tissue Embedding Universities Woman base cohort data analysis pipeline driver mutation experience genomic data imaging platform innovation liquid crystal polymer molecular pathology mouse model neoplastic cell novel novel therapeutics performance site programs reagent standard response success targeted exome sequencing therapeutic target tumor microenvironment web interface web site working group

项目摘要

PROJECT SUMMARY Core C provides access to specialized professional and technical pathology services and genomic services that are essential to the success of the Program. It does so by carrying out 3 overarching aims that support all three P01 Projects: 1) provide pathology expertise needed for classification of primary human PTCLs and PDX and murine PTCL models; 2) perform standard and novel in situ tests for biomarkers relevant to understanding PTCL pathophysiology and its response and resistance to novel therapies; and 3) perform targeted exome sequencing of a large cohort of well-characterized human PTCLs. The Core delivers these services at two performance sites, one in Boston led by Jon Aster, which will deliver services supporting Aims 1 and 2, and the second in North Carolina led by Sandeep Dave, which will deliver services supporting Aims 1 and 3. Delivery of Aim 1 services relies on the Core's co-leader, Dr. Jon Aster, who is a practicing academic hematopathologist with >25 years of experience with human and murine hematopathology, and is supplemented by additional expertise in Project 1 (John Chan) and access to the Hematologic Malignancies Research Consortium, which includes >25 institutions and has accrued over 1800 cases of T cell lymphomas, a majority with paired normal tissue. Aim 2 services will be provided in Boston include standard histology and immunohistology services and innovative, multiparametric immunofluorescence staining platforms, the Perkin- Elmer Vectra platform and CyCIF is an iterative imaging platform that allows for evaluation of >50 different markers on single FFPE slides. Aim 3 services are delivered at the North Carolina performance site by performing targeted exome sequencing on 410 genes that are frequently mutated in lymphoma, initially using DNA prepared from a cohort of 1833 PTCLs and paired normal tissue controls.

项目总结